Global Chagas Disease Management Market: By Treatment Type (Antiparasitic treatment, Symptomatic treatment), By Drug Type (Benznidazole, Nifurtimox), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Chagas Disease Management Market was valued at USD 5.72 Mn in 2021 and is expected to witness a CAGR of 7.6% over the forecast period 2022-2028. Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi. The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period. In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis  

Chagas Disease Management Market Summary

Study Period


Base Year




Largest Market

Latin America

Fastest Growing Market

–North America
Chagas Disease Management Market Dynamics

Benznidazole is a vital antiparasitic medication used to treat Chagas disease. The Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved benznidazole, a medication developed by Laboratorio Elea Phoenix SA, for paediatric use in the treatment of Chagas disease in April 2018. Argentina now has the highest number of people infected with the Chagas disease. According to data given by Mundo Sano (an Argentine non-governmental organisation), over 7,300,000 people in Argentina were exposed to Chagas disease in 2017, with about 1,600,000 becoming infected. As a result, new drug approvals are projected to drive market growth in the near future.The approval of medications to treat Chagas disease is projected to drive the Chagas Disease Management Market's growth in the near future. The campaign aims to raise public awareness about Chagas disease, which is still widespread in Latin American countries and affects around 6 million people worldwide. The World Health Organization (WHO) initiated a programme in 2007 to raise Chagas disease treatment rates and eradicate the disease. Bayer HealthCare, which makes the drug nifurtimox, which is used to treat Chagas disease, contributed to this WHO initiative. From 2012 through 2017, Bayer is expected to distribute 5 million tablets free of charge, according to the deal. In the foreseeable future, such initiatives are projected to boost market expansion.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Chagas Disease Management Market Segmentation

treatment type
  • Antiparasitic treatment
  • Symptomatic treatment
drug type
  • Benznidazole
  • Nifurtimox
Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
North America
  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
Middle East and Africa (MEA)
  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

The chagas disease management market is projected to expand at a CAGR of 7.6% during the forecast period.  

AstraZeneca, Bayer AG, Daiichi Sankyo Company Ltd, Eisai Co Ltd, GlaxoSmithKline Plc., Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Kancera AB

[urltag url='request-table-of-content']

  • AstraZeneca (U.K)
  • Bayer AG (Germany)
  • Daiichi Sankyo Company Ltd (Japan)
  • Eisai Co Ltd (Japan)
  • GlaxoSmithKline Plc. (U.K)
  • Grupo Praxis Pharmaceutical SA (Spain)
  • KaloBios Pharmaceuticals, Inc. (U.S.)
  • Kancera AB (Sweden)
  • Novartis AG (Switzerland)
  • Laboratorio Elea S.A.C.I.F. y A (Argentina)
  • Oblita Therapeutics BVBA (Belgium)
  • Sanofi (France)